Zobrazeno 1 - 10
of 180
pro vyhledávání: '"Kristof Chwalisz"'
Publikováno v:
F&S Reports, Vol 4, Iss 2, Pp 33-39 (2023)
Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been s
Externí odkaz:
https://doaj.org/article/d7d62ce674c943f8b7b81c9f9dc295c6
Publikováno v:
F&S Reports, Vol 4, Iss 2, Pp 65-72 (2023)
Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in co
Externí odkaz:
https://doaj.org/article/4be9a7574ba34e8082fc0e2d31f36784
Publikováno v:
Reproductive Sciences. 25:1567-1576
Daily diary-based dysmenorrhea and nonmenstrual pelvic pain impact items were developed and validated to measure efficacy in endometriosis clinical trial settings. Items were developed across 3 stages of qualitative research, and their psychometric p
Autor:
Charlotte D. Owens, Nelson B. Watts, Ahmed M. Soliman, Matthew B. Dufek, Michael P. Diamond, Ayman Al-Hendy, W. Rachel Duan, David F. Archer, Jingjing Gao, Linda D. Bradley, Bruce R. Carr, Elizabeth A. Stewart, James A. Simon, Kristof Chwalisz
Publikováno v:
Obstet Gynecol
To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas.This double-blind
Autor:
David F. Archer, Sanjay K. Agarwal, Keith Gordon, Eric S. Surrey, Yabing Mai, Sukhbir S. Singh, Kristof Chwalisz
Publikováno v:
Journal of Pain Research
Sanjay K Agarwal,1 Sukhbir S Singh,2 David F Archer,3 Yabing Mai,4 Kristof Chwalisz,5 Keith Gordon,6 Eric Surrey7 1Department of Obstetrics and Gynecology and Reproductive Sciences, Center for Endometriosis Research and Treatment, UC San Diego, La Jo
Autor:
Hugh S. Taylor, Kristof Chwalisz
Publikováno v:
Seminars in Reproductive Medicine. 35:510-522
Uterine fibroids (leiomyomata) are common uterine neoplasms that are often associated with detrimental symptoms, such as heavy menstrual bleeding, dysmenorrhea, and pressure-related symptoms, which often lead to surgical intervention, including hyste
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 102:1683-1691
Context Elagolix is a nonpeptide, oral gonadotropin-releasing hormone (GnRH) antagonist being developed for sex-hormone-dependent diseases in women. Objective We evaluated the pharmacokinetics and pharmacodynamics of elagolix. Design, setting, and pa
Publikováno v:
Pain management. 9(5)
Endometriosis is an estrogen-dependent chronic inflammatory disease associated with pelvic pain symptoms that are often severe, mainly dysmenorrhea, nonmenstrual pelvic pain and dyspareunia. This condition is also associated with peripheral and centr
Autor:
Eve C. Feinberg, Cheri E. Klein, Robert A. Feldman, Juki Ng, David F. Archer, Yi-Lin Chiu, Kristof Chwalisz, Charles E. Miller
Publikováno v:
The Journal of clinical endocrinology and metabolism. 105(3)
Context Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids. Objective The objecti
Autor:
Michael P. Diamond, Evan R. Myers, Kristof Chwalisz, Elizabeth A. Stewart, Alistair R.W. Williams, Bruce R. Carr, Robert A. Feldman, B. Schwefel, C. Mattia-Goldberg, W Elger
Publikováno v:
Human Reproduction Open
STUDY QUESTION What is the safety and efficacy profile during long-term (12–24 months) uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 and 25 mg in women with heavy menstrual bleeding (HMB) associated with